Trial register facet
Phase 3 trial records — page 7
351 records at phase 3.
Showing 0 records on this page
Records
351 documents · page 7 of 15
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| PIONEER-6 | Semaglutide, oral | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 3,183 | 2019 | High |
| REWIND | Dulaglutide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 9,901 | 2019 | High |
| RECONNECT-301 | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 626 | 2019 | Moderate |
| RECONNECT-302 | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 630 | 2019 | Moderate |
| PIONEER-1-REGIONAL-CNprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| PIONEER-6-BIOMARKERprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| REWIND-REGIONAL-JPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| RECONNECT-301-BODY-COMPprogramme record | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| PIONEER-1-QOLprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| PIONEER-6-ADHERENCEprogramme record | Semaglutide, oral | Phase 3 | Reported | Observational | — | 2019 | Very low |
| RECONNECT-301-REGIONAL-JPprogramme record | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| PIONEER-1-BODY-COMPprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| PIONEER-6-OLEprogramme record | Semaglutide, oral | Phase 3 | Reported | Single-arm open-label | — | 2019 | Very low |
| REWIND-QOLprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| RECONNECT-301-REGIONAL-CNprogramme record | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| PIONEER-1-REGIONAL-JPprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| PIONEER-6-ELDERLYprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| REWIND-REGIONAL-CNprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| RECONNECT-301-QOLprogramme record | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| PIONEER-6-REGIONAL-JPprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| REWIND-BIOMARKERprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| RECONNECT-301-ADHERENCEprogramme record | PT-141 (bremelanotide) | Phase 3 | Reported | Observational | — | 2019 | Very low |
| SUSTAIN-7 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, active-controlled | 1,201 | 2018 | High |
| AWARD-7 | Dulaglutide | Phase 3 | Reported | Randomised, open-label, active-controlled | 576 | 2018 | Low |
page 7 of 15